Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Operating Income (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Operating Income data on record, last reported at -$41.0 million in Q2 2025.

  • For Q2 2025, Operating Income fell 38.63% year-over-year to -$41.0 million; the TTM value through Jun 2025 reached -$157.3 million, down 18.75%, while the annual FY2025 figure was -$111.3 million, 23.56% up from the prior year.
  • Operating Income reached -$41.0 million in Q2 2025 per TNGX's latest filing, up from -$42.5 million in the prior quarter.
  • Across five years, Operating Income topped out at -$770235.0 in Q2 2021 and bottomed at -$42.5 million in Q1 2025.
  • Average Operating Income over 5 years is -$28.3 million, with a median of -$29.7 million recorded in 2022.
  • The widest YoY moves for Operating Income: up 26.86% in 2021, down 163085.38% in 2021.
  • A 5-year view of Operating Income shows it stood at -$22.0 million in 2021, then tumbled by 39.04% to -$30.6 million in 2022, then fell by 14.55% to -$35.0 million in 2023, then fell by 16.84% to -$40.9 million in 2024, then fell by 0.14% to -$41.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were -$41.0 million in Q2 2025, -$42.5 million in Q1 2025, and -$40.9 million in Q4 2024.